medivant healthcare semaglutide Use of new diet drugs

Based on what the platform advertises, VivioMD may be relevant to people interested in telehealth-based GLP-1 access without insurance, who prefer a remote assessment over an in-person clinic visit, who are open to weighing compounded options against FDA-approved brand-name pathways, and who want ongoing provider messaging between visits

In Study 8, at Week 72, the body weight was missing for 5.5%, 6.0% and 15.0% of patients randomized to WEGOVY 7.2 mg, WEGOVY 2.4 mg and placebo, respectively

Points to cover when counselling Explain mechanism of action: appetite suppression and delayed gastric emptying

Thirty-eight percent cited the costs associated with GLP-1s as a potential barrier to providing coverage